A new regulation for the Falsified Medicines Directive has been published in the Official Journal of the European Union on the 9th of February 2016, affecting all those producing pharma packaging.
Commission Delegated Regulation (EU) 2016/161 introduces two safety features that must be on the packaging of most prescription medicines and certain non-prescription medicines for human use. The features include: a unique identifier (a two-dimensional barcode) and an anti-tampering device.
The packaging must be compliant before the 9th of February 2019. The objectives are to ensure the authenticity of medicines for the benefit of patients and businesses, as well as strengthening the security of the medicine supply chain - from manufacturers to distributors, to pharmacies, hospitals and patients.
Avery Dennison offers a range of tamper-evident labelling and brand protection solutions specifically for the pharma segment. They help to ensure compliance throughout the entire supply chain, and provide the high performance needed by what are often challenging applications.
For more information on the new regulation and how to address the revised requirements, please contact your usual Avery Dennison representative.